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In breast cancers that become resistant to endocrine
therapy, oestrogen receptor (ER) signalling still plays a
crucial role in many tumours. Evidence has started to
emerge that the various signalling pathways ‘‘cross-talk’’
at several levels with the ER pathway, and that this in-
teraction becomes the dominant pathway when tumours
become resistant to endocrine therapy [1]. Peptide
growth factor pathways (such as HER2 or epidermal
growth factor receptor (EGFR)) can directly/indirectly
interact with ER and its transcription machinery, in
particular by phosphorylation and activation of the ER
protein at speciﬁc sites, or by activation of one of ERs
major co-activator proteins [2–5]. Both the mitogen ac-
tivated protein kinase (MAPK)/ERK pathway, which
may be activated by upstream growth factors, such as
HER-2 and EGFR, the AKT/PI-3 kinase pathway,
which may be activated by the insulin-like growth factor
pathway, and the p38 MAPK pathway, activated by
stress or various cytokines, can all phosphorylate ER at
key positions in the AF-1 and other domains of the re-
ceptor. Growth factor signalling may activate ER via
phosphorylation and activation of the co-activator
AIB1, and evidence from clinical studies has suggested
that co-expression of AIB1 with HER2 predicted for a
worse outcome in patients treated with tamoxifen after
surgery [5].
Data are also accumulating that suggest that changes
in these growth factor receptor pathways may occur in
tumours that develop acquired resistance to tamoxifen
over time. In the laboratory, enhanced expression of
EGFR and subsequent downstream MAPK activation
has been found in MCF-7 breast cancer cells that be-
come resistant over time to tamoxifen, with evidence
that co-treatment with the EGFR receptor tyrosine ki-
nase inhibitor ZD1839 (geﬁtinib) may prevent or delay
this resistance by blocking this signalling pathway [2,3].
More recently, changes in intra-cellular signalling in
clinical samples from breast cancer patients taken before
and at the time of relapse on adjuvant tamoxifen several
years later were reported [6]. In tumours with retained
ER expression, there was enhanced expression of HER-2
in some patients, with evidence in these tumours that the
stress-activated kinase p38 MAPK was enhanced.
Because tamoxifen can still bind and partially acti-
vate ER, in cells that co-express ER and HER2/EGFR,
an enhanced ‘agonist’ response to tamoxifen may occur
via cross-talking pathways. In contrast, complete oes-
trogen deprivation in these cells would prevent ER ac-
tivation (membrane or nuclear DNA bound), thus
eﬀectively abrogating any cross-talk activation of ER
signalling with peptide growth factor pathways [7]. As
such, this may explain the diﬀerences observed in eﬃ-
cacy between tamoxifen and aromatase inhibitors in a
neo-adjuvant clinical trial of 4 months of letrozole ver-
sus tamoxifen, especially in the subset of ER-positive
tumours that over-expressed HER2/EGFR (tumour re-
gression rates 88% letrozole vs 9% tamoxifen) [8]. These
clinical data support the concept that HER2 over-
expression in ER+ve breast cancer may account for re-
sistance to tamoxifen.
While oestrogen deprivation with aromatase in-
hibitors may be more eﬀective than tamoxifen and cir-
cumvent some of the resistance pathways described
above by removing all available ligand for ER, it is
known that hormone-sensitive breast carcinomas trea-
ted with aromatase inhibitors will in-time also acquire
endocrine resistance and start to re-grow [7]. In part,
this is caused by an adaptive increase in ER expression
and function, but there is similar evidence for increased
‘‘cross-talk’’ between various growth factor receptor
signalling pathways and ER at the time of relapse, with
ER becoming activated and super-sensitised by a num-
ber of diﬀerent intracellular kinases, including MAPK
and the insulin-like growth factor (IGF)/AKT pathway
[9–12]. Increased expression of HER2/HER3, MAPK,
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and IGFR signalling in cells that become resistance to
oestrogen deprivation may activate residual and en-
hanced levels of ER in a manner similar to that observed
in acquired tamoxifen-resistant cells. ‘Proof of principle’
has then been provided by evidence that ER-mediated
gene transcription (which is enhanced 10-fold in these
cells) can be abrogated by a number of diﬀerent ap-
proaches to interrupt upstream signalling, including
geﬁtinib, the MEK inhibitor UO126, and the ER
downregulator fulvestrant which degrades the receptor
[12]. Thus, once again, it would appear that the ER re-
mains an integral part of signalling, even following
failure of oestrogen deprivation.
These clinical and laboratory data support a concept
that, over time, breast cancer cells utilise alternative in-
tra-cellular signalling pathways to enhance and activate
the ER, and, in particular, that this allows cells to escape
from their initial endocrine therapy. Strategies to block
these signalling pathways from the outset by co-treat-
ment with geﬁtinib, in addition to tamoxifen, have been
shown in vitro and in vivo to delay resistance to tamoxifen
[13], and this approach is now being tested prospectively
in a randomised controlled trial in the clinic.
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